Related Experiment Video
Updated: May 21, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury
Yoshihisa Ogawa1, Masashi Mukoyama, Hideki Yokoi
1Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Japan.
Insights
Natriuretic peptides protect the kidneys by inhibiting the renin-angiotensin-aldosterone system and oxidative stress. Blocking these pathways in mice with high aldosterone and salt prevented kidney damage and reduced protein in urine.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Natriuretic peptides (NPs) offer cardioprotection and renoprotection via natriuresis, blood pressure reduction, and anti-fibrotic effects.
- The role of NP antagonism of the renin-angiotensin-aldosterone system (RAAS) in renoprotection remains unclear.
Purpose of the Study:
- To investigate the renoprotective mechanisms of the natriuretic peptide/guanylyl cyclase-A (GC-A) system.
- To examine the impact of RAAS and oxidative stress in GC-A knockout mice under high aldosterone and salt conditions.
Main Methods:
- Utilized GC-A knockout and wild-type mice subjected to aldosterone infusion and high-salt diet.
- Administered hydralazine, RAAS blockade, and the antioxidant tempol.
- Performed histological analysis and in vitro podocyte studies.
Main Results:
- GC-A knockout mice developed accelerated hypertension and severe proteinuria, unlike wild-type mice.
- Histological analysis revealed mesangial expansion, sclerosis, podocyte injury, and oxidative stress in knockout mice.
- RAAS blockade and tempol treatment significantly reduced albuminuria, improved podocyte injury, and decreased oxidative stress.
Conclusions:
- The endogenous natriuretic peptide/GC-A system confers renoprotection.
- Local inhibition of RAAS and oxidative stress in podocytes are key mechanisms underlying NP renoprotection.
Abstract:
Natriuretic peptides produced by the heart in response to cardiac overload exert cardioprotective and renoprotective effects by eliciting natriuresis, reducing BP, and inhibiting cell proliferation and fibrosis. These peptides also antagonize the renin-angiotensin-aldosterone system, but whether this mechanism contributes to their renoprotective effect is unknown. Here, we examined the kidneys of mice lacking the guanylyl cyclase-A (GC-A) receptor for natriuretic peptides under conditions of high aldosterone and high dietary salt. After 4 weeks of administering aldosterone and a high-salt diet, GC-A knockout mice, but not wild-type mice, exhibited accelerated hypertension with massive proteinuria. Aldosterone-infused GC-A knockout mice had marked mesangial expansion, segmental sclerosis, severe podocyte injury, and increased oxidative stress. Reducing the BP with hydralazine failed to lessen such changes; in contrast, blockade of the renin-angiotensin-aldosterone system markedly reduced albuminuria, ameliorated podocyte injury, and reduced oxidative stress. Furthermore, treatment with the antioxidant tempol significantly reduced albuminuria and abrogated the histologic changes. In cultured podocytes, natriuretic peptides inhibited aldosterone-induced mitogen-activated protein kinase phosphorylation. Taken together, these results suggest that renoprotective properties of the endogenous natriuretic peptide/GC-A system may result from the local inhibition of the renin-angiotensin-aldosterone system and oxidative stress in podocytes.
More Related Videos
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Hormonal Regulation
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
GPCRs Regulate Adenylyl Cylase Activity
Two...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

